I just finished my biochemicals article, which will be included in the National Petrochemical and Refineries Association (NPRA) supplement to be distributed on March 28 at their international meeting in San Antonio, Texas.
The article focuses on the commercialization advancement of succinic acid, biobased 1,4 butanediol (BDO) and bio-acrylic acid. With Metabolix, I was actually surprised how advanced the company's commercialization goals for their C4 chems focusing on the pyrrolidones and BDO segment of the market. Metabolix just announced its Q4 and 2010 earnings yesterday.
The company tailors its polyhydroxyalkanoates (PHAs) technology to produce a range of C2-C5 chemicals using a common fermentation and recovery process. Metabolix says it will first focus on C4s and C3s.
More on this post...